Diclofenac formulations and methods of use
DCFirst Claim
Patent Images
1. A method of treating phonophobia and photophobia in a human patient in need thereof comprising:
- a) providing an oral formulation comprising one or more pharmaceutically acceptable excipients and 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said one or more pharmaceutically acceptable excipients comprises a buffering or alkalizing agent, further wherein said formulation has been shown to achieve a Cmax of from about 1500 to about 2500 ng/ml and tmax in from about 10 to about 25 minutes; and
b) orally administering said formulation to a patient suffering from phonophobia and photophobia wherein said tmax and Cmax are mean values obtained from a plurality of human patients.
0 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
23 Citations
19 Claims
-
1. A method of treating phonophobia and photophobia in a human patient in need thereof comprising:
- a) providing an oral formulation comprising one or more pharmaceutically acceptable excipients and 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said one or more pharmaceutically acceptable excipients comprises a buffering or alkalizing agent, further wherein said formulation has been shown to achieve a Cmax of from about 1500 to about 2500 ng/ml and tmax in from about 10 to about 25 minutes; and
b) orally administering said formulation to a patient suffering from phonophobia and photophobia wherein said tmax and Cmax are mean values obtained from a plurality of human patients. - View Dependent Claims (2, 3, 4, 5)
- a) providing an oral formulation comprising one or more pharmaceutically acceptable excipients and 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said one or more pharmaceutically acceptable excipients comprises a buffering or alkalizing agent, further wherein said formulation has been shown to achieve a Cmax of from about 1500 to about 2500 ng/ml and tmax in from about 10 to about 25 minutes; and
-
6. A method of treating recurrent migraine in a human patient in need thereof suffering from migraine comprising:
- a) providing an oral formulation comprising one or more pharmaceutically acceptable excipients and 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said one or more pharmaceutically acceptable excipients comprises a buffering or alkalizing agent, further wherein said formulation has been shown to achieve a Cmax of from about 1500 to about 2500 ng/ml and tmax in from about 10 to about 25 minutes; and
b) orally administering said formulation to a patient requiring sustained migraine relief for at least 24 hours. - View Dependent Claims (7, 8, 9, 10, 11, 12)
- a) providing an oral formulation comprising one or more pharmaceutically acceptable excipients and 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said one or more pharmaceutically acceptable excipients comprises a buffering or alkalizing agent, further wherein said formulation has been shown to achieve a Cmax of from about 1500 to about 2500 ng/ml and tmax in from about 10 to about 25 minutes; and
-
13. A method of treating headache pain, nausea, photophobia and phonophobia in a human patient in need thereof comprising:
- a) providing an oral formulation comprising one or more pharmaceutically acceptable excipients and 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said one or more pharmaceutically acceptable excipients comprise a buffering or alkalizing agent wherein said formulation has been shown to achieve a Cmax of from about 1500 to about 2500 ng/ml and tmax in from about 10 to about 25 minutes; and
b) orally administering said formulation to a patient suffering from headache pain, nausea, photophobia and phonophobia. - View Dependent Claims (14, 15, 16, 17, 18, 19)
- a) providing an oral formulation comprising one or more pharmaceutically acceptable excipients and 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said one or more pharmaceutically acceptable excipients comprise a buffering or alkalizing agent wherein said formulation has been shown to achieve a Cmax of from about 1500 to about 2500 ng/ml and tmax in from about 10 to about 25 minutes; and
Specification